Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2.

What was studied

This paper looked at remibrutinib, a pill for chronic spontaneous urticaria (CSU). It pooled data from 2 phase 3 trials, REMIX-1 and REMIX-2. The adults in them still had symptoms despite antihistamine drugs. By chance, people got remibrutinib or a dummy pill. The dose was 25 mg by mouth, 2 times a day. Neither people nor staff knew who got which, for 24 weeks. Then all took remibrutinib for 28 more weeks, with 4 weeks off drug after. People filled in forms on symptoms, sleep, daily life and work.

What they found

The analysis had 606 people on remibrutinib and 306 on dummy pills. Within 1 week, symptom scores dropped more with remibrutinib than with dummy pills. Sleep scores also improved more with remibrutinib in that first week. Scores for disease control, daily life, skin-related life quality and work improved too. These gains showed at the first time points checked. With remibrutinib, the gains lasted through week 52. People who switched from dummy pills to remibrutinib improved in a similar way.

What it means for patients

The authors say remibrutinib brought fast gains in disease control. They also saw fast gains in sleep and quality of life. They see it as a useful treatment choice for CSU. These trials were in adults whose symptoms went on despite antihistamines.

Why it is not certain yet

After week 24, everyone knew they were taking remibrutinib. So later results had no dummy pill group to compare against. The results come from forms people filled in about themselves. The abstract does not report side effects.

Source

Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2.

We restate facts from the source record in our own words. The original wording belongs to its publisher.